Denali Therapeutics's total assets for Q4 2024 were $1.37B, a decrease of -5.49% from the previous quarter. DNLI total liabilities were $144.50M for the fiscal quarter, a 6.62% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.